EU RISK MANAGEMENT PLAN (EU RMP)

Similar documents
RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

Package leaflet: Information for the user. Omeprazol STADA 20 mg gastro-resistant tablets Omeprazole

Losamel 20mg Gastro-resistant Tablets

Package leaflet: Information for the user Esopral 40 mg Powder for solution for injection/infusion esomeprazole

Package leaflet: Information for the user. Nexium IV 40 mg Powder for solution for injection/infusion esomeprazole

Package leaflet: Information for the patient

Package leaflet: Information for the patient

Package leaflet: Information for the patient <invented name> 20 mg Gastro-Resistant Tablets <invented name> 40 mg Gastro-Resistant Tablets

Package leaflet: Information for the user. Omeprazol Pensa 40 mg gastro-resistant capsules, hard. Omeprazole

PACKAGE LEAFLET: INFORMATION OFR THE USER. Spezato 20mg, gastro-resistant capsules, hard Omeprazole

Package leaflet: Information for the patient Nexium 40 mg gastro-resistant tablets. esomeprazole

Package leaflet: Information for the patient. Omeprazol Actavis 40 mg gastro-resistant capsules, hard. omeprazole

PACKAGE LEAFLET: INFORMATION FOR THE USER. Omeprazole Pinewood 20 mg Gastro-resistant capsules, hard Omeprazole

Package leaflet: Information for the patient

Package leaflet: Information for the user. PARIET 10 mg and 20 mg gastro-resistant tablets Rabeprazole sodium

Controloc 40 mg is used for:

Package leaflet: Information for the patient. Nexazole 40 mg gastro-resistant capsules, hard. Esomeprazole

IS AND WHAT IT IS USED FOR

PACKAGE LEAFLET: INFORMATION FOR THE USER. Losec 10 mg hard capsules Losec 20 mg hard capsules Losec 40 mg hard capsules Omeprazole

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER. ULCERBREX 10 mg mg gastro-resistant tablets Rabeprazole sodium

Package leaflet: Information for the user. Ulcerbrex 20 mg gastro-resistant tablets Rabeprazole sodium

NEXIUM INTRAVENOUS esomeprazole sodium

Package leaflet: Information for the patient

Package leaflet: Information for the patient

Package leaflet: Information for the patient. Pantoprazol Orion 20 mg gastro-resistant tablets. pantoprazole

Package leaflet: Information for the patient

Pantium 40mg Gastro-resistant Tablets

Package leaflet: Information for the user. Pantoprazole Bluefish 40 mg gastro-resistant tablets pantoprazole

This leaflet answers some of the common questions people ask about Pharmacor Omeprazole.

Package leaflet: Information for the user. Nolpaza 40 mg gastro-resistant tablets. Pantoprazole

PACKAGE LEAFLET (FOR PEELABLE BLISTER PACKAGING ONLY)

Package leaflet: Information for the patient

Package leaflet: information for the user. Rabeprazole 20 mg gastro-resistant tablets. rabeprazole sodium

Rabeprazole Clonmel 10mg Gastro-resistant Tablets Rabeprazole Clonmel 20mg Gastro-resistant Tablets

PACKAGE LEAFLET Page 1 of 7

Package leaflet: Information for the user Ventra 20 mg gastro-resistant capsules, hard Ventra 40 mg gastro-resistant capsules, hard Esomeprazole

PACKAGE LEAFLET: INFORMATION FOR THE USER LANSOPRAZOLE 15MG & 30MG GASTRO-RESISTANT CAPSULES

Omeprazole generichealth Enteric-coated Tablets

This leaflet answers some of the common questions people ask about Pharmacor Omeprazole.

COMPOSITION: Each film-coated tablet contains 500mg mefenamic acid. Also includes sunset yellow E110. See leaflet for further information.

PHARMACOR OMEPRAZOLE 20mg Enteric-coated Tablets

PACKAGE LEAFLET: INFORMATION FOR THE USER. Esomeprazol Mylan 40 mg Gastro-resistant tablets. esomeprazole

Losec Control 20 mg gastro-resistant tablets Omeprazole

INFORMATION FOR THE CONSUMER

Package leaflet: Information for the patient. Melox 10 mg/ml solution for injection meloxicam

PACKAGE LEAFLET: INFORMATION FOR THE USER

PATIENT INFORMATION LEAFLET PEPLOC RANGE

Terry White Chemists Omeprazole Contains the active ingredient omeprazole

ESOMEPRAZOLE APOTEX Esomeprazole magnesium dihydrate

PACKAGE LEAFLET Package leaflet: Information for the user. Ranitidin Actavis 150 mg and 300 mg film-coated tablets. Ranitidine

PART III: PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE. Pantoprazole Magnesium Enteric-Coated Tablets

APO-Omeprazole Contains the active ingredient omeprazole Consumer Medicine Information

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. lansoprazole delayed-release capsule (Manufacturer s standard)

OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF LOSEC AND ASSOCIATED NAMES (SEE ANNEX I)

0BCore Safety Profile. Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) NL/H/PSUR/0058/001 Date of FAR:

Esomeprazole RBX Tablets Esomeprazole magnesium

Package leaflet: Information for the user. Pantoprazole 40 mg powder for solution for injection Pantoprazole

Package leaflet: Information for the patient. Lansoprazole 15 mg orodispersible tablets. lansoprazole

PACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen

How Rabeprazole Sandoz works

Elements for a public summary

Summary of the risk management plan (RMP) for Clopidogrel/Acetylsalicylic acid Teva (clopidogrel / acetylsalicylic acid)

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. OMEPRAZOLE Omeprazole Delayed-Release Capsules

PART III: PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. OMEPRAZOLE Omeprazole Delayed-Release Capsules

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

* Adults. NSAID associated peptic ulceration: - Acute treatment: 150 mg twice daily for 8 to 12 weeks, or 300mg nocte.

Package leaflet: Information for the user. Lansoprazole 15mg Orodispersible Tablets Lansoprazole 30mg Orodispersible Tablets.

PACKAGE LEAFLET INFORMATION FOR THE USER. Cimetidine 200mg Tablets Cimetidine 400mg Tablets Cimetidine 800mg Tablets (Cimetidine)

NEW ZEALAND CONSUMER MEDICINE INFORMATION. OMEZOL RELIEF is also used to help stop reflux oesophagitis coming back or relapsing.

COMPOSITION: Each hard capsule contains 250mg mefenamic acid. Also includes lactose monohydrate. See leaflet for further information.

Etoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets , Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives

Package leaflet: Information for the patient

Package leaflet: Information for the user. Ranitidine 150 mg film-coated tablets Ranitidine 300 mg film-coated tablets. Ranitidine

0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR:

Package leaflet: Information for the patient. Rabeprazole 20 mg Gastro-resistant Tablets. (rabeprazole sodium)

Esomeprazole strontium can have other serious side effects. See What are the possible side effects of esomeprazole strontium?

srmp Atorvastatin Medical Valley

Package leaflet: Information for the user. Ranitidine Sandoz effervescent 150, 150 mg effervescent tablets Ranitidine

Diclofenac, Version 1.2. Elements for a public summary. VI.2.1 Overview of disease epidemiology

PACKAGE LEAFLET Page 1 of 9

PACKAGE LEAFLET INFORMATION FOR THE USER. Cimetidine 800mg Tablets. Cimetidine 400mg Tablets. (Cimetidine)

PACKAGE LEAFLET: INFORMATION FOR THE USER. Zoton FasTab* 15 mg oro-dispersible tablets Zoton FasTab* 30 mg oro-dispersible tablets.

BACTRIM tablets PACKAGE LEAFLET: INFORMATION FOR THE USER. What is in this leaflet? 1 WHAT BACTRIM IS AND WHAT IT IS USED FOR

Package leaflet: Information for the user. Pantoprazole 20mg Gastro-resistant Tablets

Etopan XL 600 mg tablets

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. rabeprazole sodium tablets

Non-steroidal Anti-Inflammatory Drugs (NSAIDs)

Elements for a Public Summary Overview of disease epidemiology

RANTUDIL F 60mg capsules

Transcription:

EU RISK MANAGEMENT PLAN (EU RMP) Active substance(s) (INN or common name): Esomeprazole Pharmaco-therapeutic group (ATC Code): A02B C05 Name of Marketing Authorisation Holder or Applicant: Strength and pharmaceutical form: Sigillata Limited 20mg and 40mg gastro resistant tablets Data lock point for this RMP November 2013 Version number 1.1 Date of final sign off 30/12/2013

Elements for a public summary VI.2.1 Overview of disease epidemiology Esomeprazole is a medicine which is used in adults for the treatment of reflux symptoms (sometimes called acid reflux), such as heartburn and acid regurgitation. It is also used to heal or prevent peptic ulcers in certain types of patients. This medicine works by reducing the amount of acid that the stomach produces. Gastroesophageal reflux disease Partly as a result of diet and lifestyle, some adults living in the Western world have become prone to acid reflux (acid leaking from the stomach upwards into the oesophagus or gullet). It is as common in women as in men, but more likely in people over the age of 40. Unlike the stomach, the gullet is not meant to have acid in it and so this acid leakage can damage the lining of the gullet and can cause symptoms like heartburn and may even cause the gullet to develop an ulcer. Zollinger-Ellison syndrome The disease called Zollinger-Ellison syndrome is caused by a particular type of tumour in the pancreas. This type of tumour causes the cells which produce the acid in the stomach to work more than usual and produce too much acid. As a result of this increased amount of acid, some of it can leak upwards out of the stomach into the gullet. The lining of the gullet is different from the lining of the stomach and is not protected from being damaged by the acid, meaning that it may cause symptoms like heartburn and acid reflux or acid regurgitation. Many kinds of people can be affected by this disease, but it usually occurs over the age of 40 50 years and is slightly more common in men. Peptic ulcer Stomach ulcers and duodenal ulcers (which develop in the duodenum, the next part of the bowel after the stomach) are often referred to as peptic ulcers. Peptic ulcers are quite common and about 10% (1 in 10) people will suffer from this problem at some time in their life. Peptic ulcers can affect people of any age, though they are more common over the age of 60. They can be caused by a particular type of bacteria in the stomach (called Helicobacter pylori) which irritates the lining of the stomach causing an ulcer to form; or certain kinds of drugs which can damage the stomach lining (particularly certain types of pain killers called non-steroidal anti-inflammatory drugs or NSAIDs). Drugs like esomeprazole which reduce the amount of acid in the stomach will help the ulcer to heal. VI.2.2 Summary of treatment benefits Esomeprazole has been tested in Clinical Trials in a total of over 15,000 people worldwide to be effective in each of the indications stated above. Gastro-oesophageal reflux disease Studies were conducted to test the effectiveness of esomeprazole in 6709 patients who had developed erosions (ulcers) in the gullet caused by acid reflux. Most studies compared esomeprazole with placebo (dummy treatment). The main measure of effectiveness was the healing rate of the ulcers over the first 4 and 8 weeks of the study. By the end of 8 weeks approximately 90% (9 out of 10) of patients had been healed. A further 808 patients were studied to look at long term healing of the ulcer after 6 and 12 months. Approximately 90% of patients remained healed. In 717 patients with symptoms of acid reflux, where the main measure of effectiveness was relief of symptoms of heartburn, up to 75% (three quarters) of patients were symptom free after one month.

Zollinger-Ellison syndrome A small study showed that 18 out of 20 patients tested had their acid production controlled after one year of treatment. Peptic ulcer Esomeprazole in combination with 2 antibiotics was tested in two major studies in a 10 day treatment of peptic ulcer caused by Helicobacter pylori. In each study the bacteria were cleared in approximately 84% of patients after one month. In those patients, the peptic ulcer was healed at one month in 75% and 57% of patients in one or the other study. Two studies were also conducted in patients at risk of developing peptic ulcers as a result of needing to take NSAID drugs regularly. A total of 1429 patients were tested but as there was a very low incidence of ulcers in any patients it was impossible to see whether or not esomeprazole helped. VI.2.3 Unknowns relating to treatment benefits Based on the currently available data, there is no evidence to suggest that treatment results would be different in any subgroup of the studied population, taking i n t o a c c o u n t factors such as a g e, s e x, r a c e, or o r g a n impairment. Limited data is available regarding treatment in children and the effects of long-term treatment. VI.2.4 Summary of safety concerns Important identified risks

Risk What is known Preventability Lack of white blood cells (Agranulocytosis) Allergic reactions (Hypersensitivity reactions) Low levels of magnesium in the blood (Hypomagnesaemia) Low mood (Depression) Wheezing and shortness of breath (Bronchospasm) Liver problems, including jaundice (Hepatitis) Changes in the blood count including agranulocytosis (lack of white blood cells) are very rare and may affect up to 1 in 10,000 In people allergic to esomeprazole or any of the ingredients, an allergic reaction may develop. Signs of an allergic reaction include sudden wheezing, swelling of the lips, tongue and throat or body, rash, fainting or difficulties in swallowing. Treatment for longer than three months may cause the levels of magnesium in the blood to fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Esomeprazole may cause a person to be depressed. This is rare and can affect up to 1 in 1,000 This is rare and may affect up to 1 in 1,000 There is a potential for patients to develop side effects relating to the liver during treatment with esomeprazole. Symptoms may include yellow skin, dark urine and tiredness. Esomeprazole may in very rare cases affect the white blood cells leading to immune deficiency. A lack of white blood cells (agranulocytosis) can be ruled out by a blood test. Esomeprazole should not be used in patients with a history of an allergic reaction to this medicine or any of its ingredients. If any signs of an allergic reaction develop, the medicine should be stopped immediately. If any of these symptoms develop, a doctor should be informed promptly. Regular blood tests may be required to monitor the levels of magnesium. If these symptoms occur contact the doctor.

Risk What is known Preventability Lack of white blood cells (Agranulocytosis) Allergic reactions (Hypersensitivity reactions) Low levels of magnesium in the blood (Hypomagnesaemia) Low mood (Depression) Wheezing and shortness of breath (Bronchospasm) Liver failure (Hepatic failure) Changes in the blood count including agranulocytosis (lack of white blood cells) are very rare and may affect up to 1 in 10,000 In people allergic to esomeprazole or any of the ingredients, an allergic reaction may develop. Signs of an allergic reaction include sudden wheezing, swelling of the lips, tongue and throat or body, rash, fainting or difficulties in swallowing. Treatment for longer than three months may cause the levels of magnesium in the blood to fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Esomeprazole may cause a person to be depressed. This is rare and can affect up to 1 in 1,000 This is rare and may affect up to 1 in 1,000 Severe liver problems leading to liver failure may affect up to 1 in 10,000 Esomeprazole may in very rare cases affect the white blood cells leading to immune deficiency. A lack of white blood cells (agranulocytosis) can be ruled out by a blood test. Esomeprazole should not be used in patients with a history of an allergic reaction to this medicine or any of its ingredients. If any signs of an allergic reaction develop, the medicine should be stopped immediately. If any of these symptoms develop, a doctor should be informed promptly. Regular blood tests may be required to monitor the levels of magnesium. Patients with severe liver problems may require a lower dose.

Risk What is known Preventability Lack of white blood cells (Agranulocytosis) Allergic reactions (Hypersensitivity reactions) Low levels of magnesium in the blood (Hypomagnesaemia) Low mood (Depression) Wheezing and shortness of breath (Bronchospasm) Inflammation of the brain due to liver failure (Hepatic encephalopathy) Changes in the blood count including agranulocytosis (lack of white blood cells) are very rare and may affect up to 1 in 10,000 In people allergic to esomeprazole or any of the ingredients, an allergic reaction may develop. Signs of an allergic reaction include sudden wheezing, swelling of the lips, tongue and throat or body, rash, fainting or difficulties in swallowing. Treatment for longer than three months may cause the levels of magnesium in the blood to fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Esomeprazole may cause a person to be depressed. This is rare and can affect up to 1 in 1,000 This is rare and may affect up to 1 in 1,000 Severe liver problems leading to liver failure and inflammation of the brain may affect up to 1 in 10,000 Esomeprazole may in very rare cases affect the white blood cells leading to immune deficiency. A lack of white blood cells (agranulocytosis) can be ruled out by a blood test. Esomeprazole should not be used in patients with a history of an allergic reaction to this medicine or any of its ingredients. If any signs of an allergic reaction develop, the medicine should be stopped immediately. If any of these symptoms develop, a doctor should be informed promptly. Regular blood tests may be required to monitor the levels of magnesium. Patients with severe liver problems may require a lower dose.

Risk What is known Preventability Lack of white blood cells (Agranulocytosis) Allergic reactions (Hypersensitivity reactions) Low levels of magnesium in the blood (Hypomagnesaemia) Low mood (Depression) Wheezing and shortness of breath (Bronchospasm) Severe skin rash (Erythema multiforme) Severe skin rash or blistering or peeling skin Changes in the blood count including agranulocytosis (lack of white blood cells) are very rare and may affect up to 1 in 10,000 In people allergic to esomeprazole or any of the ingredients, an allergic reaction may develop. Signs of an allergic reaction include sudden wheezing, swelling of the lips, tongue and throat or body, rash, fainting or difficulties in swallowing. Treatment for longer than three months may cause the levels of magnesium in the blood to fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Esomeprazole may cause a person to be depressed. This is rare and can affect up to 1 in 1,000 This is rare and may affect up to 1 in 1,000 Sudden onset of a severe rash or blistering or peeling skin is very rare and may affect up to 1 in 10,000 Reddening of the skin with blisters or peeling may develop. There may also be severe blisters Esomeprazole may in very rare cases affect the white blood cells leading to immune deficiency. A lack of white blood cells (agranulocytosis) can be ruled out by a blood test. Esomeprazole should not be used in patients with a history of an allergic reaction to this medicine or any of its ingredients. If any signs of an allergic reaction develop, the medicine should be stopped immediately. If any of these symptoms develop, a doctor should be informed promptly. Regular blood tests may be required to monitor the levels of magnesium. Patients should be made aware

Risk What is known Preventability Lack of white blood cells (Agranulocytosis) Allergic reactions (Hypersensitivity reactions) Low levels of magnesium in the blood (Hypomagnesaemia) Low mood (Depression) Wheezing and shortness of breath (Bronchospasm) (Stevens-Johnson syndrome/toxic epidermal necrolysis) Changes in the blood count including agranulocytosis (lack of white blood cells) are very rare and may affect up to 1 in 10,000 In people allergic to esomeprazole or any of the ingredients, an allergic reaction may develop. Signs of an allergic reaction include sudden wheezing, swelling of the lips, tongue and throat or body, rash, fainting or difficulties in swallowing. Treatment for longer than three months may cause the levels of magnesium in the blood to fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Esomeprazole may cause a person to be depressed. This is rare and can affect up to 1 in 1,000 This is rare and may affect up to 1 in 1,000 and bleeding in the lips, eyes, mouth, nose and genitals. This is very rare and may affect up to 1 in 10,000 Esomeprazole may in very rare cases affect the white blood cells leading to immune deficiency. A lack of white blood cells (agranulocytosis) can be ruled out by a blood test. Esomeprazole should not be used in patients with a history of an allergic reaction to this medicine or any of its ingredients. If any signs of an allergic reaction develop, the medicine should be stopped immediately. If any of these symptoms develop, a doctor should be informed promptly. Regular blood tests may be required to monitor the levels of magnesium.

Risk What is known Preventability Lack of white blood cells (Agranulocytosis) Allergic reactions (Hypersensitivity reactions) Low levels of magnesium in the blood (Hypomagnesaemia) Low mood (Depression) Wheezing and shortness of breath (Bronchospasm) Severe kidney problems (Interstitial nephritis) Changes in the blood count including agranulocytosis (lack of white blood cells) are very rare and may affect up to 1 in 10,000 In people allergic to esomeprazole or any of the ingredients, an allergic reaction may develop. Signs of an allergic reaction include sudden wheezing, swelling of the lips, tongue and throat or body, rash, fainting or difficulties in swallowing. Treatment for longer than three months may cause the levels of magnesium in the blood to fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Esomeprazole may cause a person to be depressed. This is rare and can affect up to 1 in 1,000 This is rare and may affect up to 1 in 1,000 Severe kidney problems may develop but are very rare and may affect up to 1 in 10,000 Esomeprazole may in very rare cases affect the white blood cells leading to immune deficiency. A lack of white blood cells (agranulocytosis) can be ruled out by a blood test. Esomeprazole should not be used in patients with a history of an allergic reaction to this medicine or any of its ingredients. If any signs of an allergic reaction develop, the medicine should be stopped immediately. If any of these symptoms develop, a doctor should be informed promptly. Regular blood tests may be required to monitor the levels of magnesium. Caution is advised when treating patients with severe underlying kidney problems.

Risk What is known Preventability Lack of white blood cells (Agranulocytosis) Allergic reactions (Hypersensitivity reactions) Low levels of magnesium in the blood (Hypomagnesaemia) Low mood (Depression) Wheezing and shortness of breath (Bronchospasm) Fracture of the hip, wrist or spine Changes in the blood count including agranulocytosis (lack of white blood cells) are very rare and may affect up to 1 in 10,000 In people allergic to esomeprazole or any of the ingredients, an allergic reaction may develop. Signs of an allergic reaction include sudden wheezing, swelling of the lips, tongue and throat or body, rash, fainting or difficulties in swallowing. Treatment for longer than three months may cause the levels of magnesium in the blood to fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Esomeprazole may cause a person to be depressed. This is rare and can affect up to 1 in 1,000 This is rare and may affect up to 1 in 1,000 Proton pump inhibitors, especially if used in high doses and over long durations (>1 year), may increase the risk of hip, wrist and spine fracture, particularly in the elderly or in patients with risk factors. Esomeprazole may in very rare cases affect the white blood cells leading to immune deficiency. A lack of white blood cells (agranulocytosis) can be ruled out by a blood test. Esomeprazole should not be used in patients with a history of an allergic reaction to this medicine or any of its ingredients. If any signs of an allergic reaction develop, the medicine should be stopped immediately. If any of these symptoms develop, a doctor should be informed promptly. Regular blood tests may be required to monitor the levels of magnesium. Caution is advised in treating patients with osteoporosis or in patients being treated with corticosteroids.

Taken together with other medicines such as nelfinavir/atazanavir (used to treat HIV), phenytoin (used in epilepsy), medicines that are used to thin your blood, such as warfarin, digoxin (used for heart problems), methotrexate (a chemotherapy medicine used in high doses to treat cancer). tacrolimus and clopidogrel (Drug interaction) If these medicines are taken together with esomeprazole, they may affect the way the other medicine works. Caution is advised when taking these medicines together.

Important potential risks Risk Fits What is known There is a potential increased risk of fits particularly with a low level of magnesium in the blood. (convulsion/seizure) Use during pregnancy and the risk of asthma in children There is a potential increased risk of asthma in children if esomeprazole is used during pregnancy. (Use of acid-suppressing drugs in pregnancy and risk of childhood asthma) Missing information Risk Long term treatment in children What is known Data is lacking concerning the long term use of esomeprazole in children VI.2.5 Summary of additional risk minimisation measures by safety concern No additional risk minimisation activities are required. Routine pharmacovigilance activities are considered sufficient to monitor the benefit-risk profile of the product and detect any safety concerns. VI.2.6 Planned post authorisation development plan (if applicable) There are no studies in the post authorisation development plan.

VI.2.7 Summary of changes to the risk management plan over time Table 1. Major changes to the Risk Management Plan over time

Version Date Safety Concerns Comment Version 1.0 20/05/2013 Important identified risks Use in severe renal impairment N/A Use in severe hepatic impairment Interaction with CYP3A4 inhibitors Interaction with CYP2C19 inhibitors or inducers Gastrointestinal perforation Use in patients with gastric ulcers Psychiatric disorders Interference with laboratory tests Hypomagnesaemia Interaction with clopidogrel Increased risk of fractures Reduction of vitamin B12 absorption Co-administration with atazanavir Co-administration with warfarin

Version 1.1 Under review Important identified risks Agranulocytosis Hypersensitivity reactions Safety concerns were updated in-line with the originator product Hypomagnesaemia Depression Bronchospasm Hepatitis with or without jaundice Hepatic failure Hepatic encephalopathy Erythema multiforme Steven s Johnson syndrome/toxic epidermal necrolysis Interstitial nephritis Fracture of the hip, wrist or spine Drug interaction with warfarin or other coumarine derivatives, phenytoin, atazanavir, nelfinavir, digoxin, methotrexate, tacrolimus, clopidogrel Important potential risks Convulsion/seizure Use of acid-suppressing drugs in pregnancy and childhood asthma Missing information Long term treatment in children